Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

GE25-6600-20

Genomiphi Hy Kit

Cytiva 25-6600-20, sufficient for 100 reactions

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
41116006
NACRES:
NA.55

impiego

sufficient for 100 reactions

Produttore/marchio commerciale

Cytiva 25-6600-20

Condizioni di spedizione

dry ice

Temperatura di conservazione

−70°C

Descrizione generale

Illustra GenomiPhi HY DNA Amplification Kit offers highly efficient and representative whole-genome amplification with 40 to 50 μg yield from nanogram amounts of DNA sample.

illustra GenomiPhi HY DNA Amplification Kit is part of the Phi29 DNA polymerase family of products from Cytiva. It contains all of the components necessary for midi-scale whole genome amplification by isothermal strand displacement amplification.

Amplification is highly uniform over the entire genome so that locus representation remains extremely close to the original DNA sample. Furthermore, amplification is carried out with very high fidelity due to Phi29 DNA polymerase proofreading activity.

The illustra GenomiPhi HY DNA Amplification Kit procedure is quick, simple and does not require a thermal cycler. A typical DNA yield of 40 to 50 μg DNA can be achieved in four h with little hands-on time. The average product length is over 10 kb. The starting material for GenomiPhi reactions can be purified DNA from any commercial kit or homebrew method, or a nonpurified cell lysate may be used. The kit was verified with DNA from various clinical samples including blood and buccal swabs.

Applicazioni

GenomiPhi amplified DNA is suitable for various applications such as genotyping (SNP, STR, array CGH), cloning, sequencing, and DNA archiving.

Caratteristiche e vantaggi

  • Representative isothermal amplification of the whole genome.
  • No template-independent, background amplification product.
  • Outperforms PCR-based whole genome amplification techniques.
  • Quick and simple automation-friendly protocol; no thermal cycler required.
  • Yields high-quality DNA (e.g., for high-throughput genotyping, hybridization, and DNA archival).

Stoccaggio e stabilità

Please be aware this product may be shipped 90 days before the expiration date. For more information on the batch specific expiration date, please contact technical service.
S-re the kit at -70°C. The enzyme mix must be s-red at -70°C; all other components may be s-red at -20°C Thaw components on ice and maintain at 0°C - 4°C during handling

Risultati analitici

To view the Certificate of Analysis for this product, please visit www.cytiva.com.

Note legali

GenomiPhi
On packaging and insert:
For use only as licensed by Qiagen GmbH. and Cytiva. The Phi 29 DNA polymerase may not be re-sold or used except in conjunction with the other components of this kit. See US patent numbers 5,854,033, 6,124,120, 6,143,495, 6,323,009, 5,576,204, and equivalent patents and patent applications in other countries.
On container:
Subject to proprietary rights of Cytiva. May not be re-sold or used except with the other components of this kit. See US patent numbers 5,576,204, and equivalent patents and patent applications in other countries.
GenomiPhi is a trademark of Cytiva
illustra is a trademark of Cytiva

Codice della classe di stoccaggio

12 - Non Combustible Liquids


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Enrico Tiacci et al.
Haematologica, 98(4), 635-639 (2013-01-26)
The BRAF-V600E mutation defines genetically hairy cell leukemia among B-cell leukemias and lymphomas. In solid tumors, BRAF-V600E is known to aberrantly activate the oncogenic MEK-ERK pathway, and targeted BRAF and/or MEK inhibitors have shown remarkable efficacy in clinical trials in
Jennifer Yen et al.
Genome biology, 14(10), R113-R113 (2013-10-24)
Melanoma is the most deadly form of skin cancer. Expression of oncogenic BRAF or NRAS, which are frequently mutated in human melanomas, promote the formation of nevi but are not sufficient for tumorigenesis. Even with germline mutated p53, these engineered
Jeffrey S McLean et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(26), E2390-E2399 (2013-06-12)
The "dark matter of life" describes microbes and even entire divisions of bacterial phyla that have evaded cultivation and have yet to be sequenced. We present a genome from the globally distributed but elusive candidate phylum TM6 and uncover its
Yanping Lu et al.
PloS one, 8(9), e73245-e73245 (2013-09-17)
Meckel-Gruber syndrome type 3 is an autosomal recessive genetic defect caused by mutations in TMEM67 gene. In our previous study, we have identified a homozygous TMEM67 mutation in a Chinese family exhibiting clinical characteristics of MKS3, which provided a ground
Michael S Fitzsimons et al.
Genome research, 23(5), 878-888 (2013-03-16)
The majority of microbial genomic diversity remains unexplored. This is largely due to our inability to culture most microorganisms in isolation, which is a prerequisite for traditional genome sequencing. Single-cell sequencing has allowed researchers to circumvent this limitation. DNA is

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.